About Shire PLC (NASDAQ:SHPG)
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:SHPG
- CUSIP: N/A
- Web: www.shire.com
- 52 Week Range: $139.36 - $192.64
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 9.42
- P/E Growth: 0.00
- Annual Dividend: $0.92
- Dividend Yield: 0.6%
- Net Margins: 4.70%
- Return on Equity: 14.10%
- Return on Assets: 6.25%
- Debt-to-Equity Ratio: 0.59%
- Current Ratio: 0.96%
- Quick Ratio: 0.52%
Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)
What is Shire PLC's stock symbol?
Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."
How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?
Shire PLC announced a semiannual dividend on Friday, August 11th. Stockholders of record on Friday, September 8th will be paid a dividend of $0.1527 per share on Friday, October 20th. This represents a dividend yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. View Shire PLC's Dividend History.
How were Shire PLC's earnings last quarter?
Shire PLC (NASDAQ:SHPG) posted its earnings results on Friday, October, 27th. The company reported $3.37 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $3.66 by $0.29. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. View Shire PLC's Earnings History.
When will Shire PLC make its next earnings announcement?
What guidance has Shire PLC issued on next quarter's earnings?
Shire PLC issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus estimate of $14.85. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $15.04 billion.
Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?
20 brokers have issued twelve-month price objectives for Shire PLC's stock. Their predictions range from $159.00 to $325.00. On average, they anticipate Shire PLC's stock price to reach $220.91 in the next twelve months. View Analyst Ratings for Shire PLC.
What are analysts saying about Shire PLC stock?
Here are some recent quotes from research analysts about Shire PLC stock:
- 1. Cantor Fitzgerald analysts commented, "This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP)." (8/15/2017)
- 2. According to Zacks Investment Research, "Shire reported encouraging Q2 results, beating estimates for both sales and earnings.The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 23% of the total market by the end of Jun 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry." (8/8/2017)
- 3. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)
Are investors shorting Shire PLC?
Shire PLC saw a increase in short interest in September. As of September 15th, there was short interest totalling 2,423,090 shares, an increase of 57.8% from the August 31st total of 1,535,236 shares. Based on an average trading volume of 1,397,911 shares, the short-interest ratio is presently 1.7 days.
Who are some of Shire PLC's key competitors?
Some companies that are related to Shire PLC include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), Novo Nordisk A/S (NVO), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA) and Dr. Reddy's Laboratories Ltd (RDY).
Who are Shire PLC's key executives?
Shire PLC's management team includes the folowing people:
- Flemming Ornskov M.D., Chief Executive Officer, Executive Director
- Jeffrey Poulton, Chief Financial Officer, Executive Director
- Joanne Cordeiro, Chief Human Resource Officer
- William Mordan, General Counsel, Company Secretary
- Perry Sternberg, Head - U.S. Commercial
- Kim Stratton, Head - International Commercial
- Philip J. Vickers, Head - Research and Development
- Matthew Walker, Head - Technical Operations
- Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
- Olivier Bohuon, Non-Executive Director
How do I buy Shire PLC stock?
Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Shire PLC's stock price today?
MarketBeat Community Rating for Shire PLC (NASDAQ SHPG)MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Shire PLC stock can currently be purchased for approximately $152.05.
Consensus Ratings for Shire PLC (NASDAQ:SHPG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||7 Hold Ratings, 13 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.65)|
|Consensus Price Target: ||$220.91 (45.29% upside)|Consensus Price Target History for Shire PLC (NASDAQ:SHPG)
Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
(Data available from 10/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/11/2017||Royal Bank Of Canada||Reiterated Rating||Outperform -> Outperform||$213.00||N/A|
|10/8/2017||Stifel Nicolaus||Reiterated Rating||Buy||$245.00||N/A|
|9/14/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$222.00||Low|
|8/16/2017||Evercore ISI||Initiated Coverage||Outperform -> Outperform||$196.00||Medium|
|8/11/2017||Barclays PLC||Downgrade||Overweight -> Equal Weight||Low|
|8/9/2017||Jefferies Group LLC||Reiterated Rating||Hold||$216.00 -> $206.00||Low|
|7/26/2017||Piper Jaffray Companies||Set Price Target||Hold||$159.00||Medium|
|7/17/2017||BTIG Research||Reiterated Rating||Buy||$242.00||Low|
|7/13/2017||Sanford C. Bernstein||Reiterated Rating||Market Perform||$210.00||Low|
|7/6/2017||HSBC Holdings plc||Upgrade||Reduce -> Hold||Medium|
|6/1/2017||Liberum Capital||Downgrade||Buy -> Hold||Low|
|5/31/2017||Cowen and Company||Reiterated Rating||Outperform||$325.00||Low|
|4/17/2017||Goldman Sachs Group, Inc. (The)||Boost Price Target||Overweight||$202.00 -> $214.00||Low|
|12/2/2016||Societe Generale||Initiated Coverage||Buy||N/A|
|11/14/2016||Leerink Swann||Set Price Target||Buy||$198.00||N/A|
|11/7/2016||J P Morgan Chase & Co||Reiterated Rating||Overweight||N/A|
|11/3/2016||Citigroup Inc.||Reiterated Rating||Buy||N/A|
|11/2/2016||Deutsche Bank AG||Reiterated Rating||Buy||N/A|
|10/23/2016||BNP Paribas||Reiterated Rating||Buy||N/A|
|10/8/2016||Shore Capital||Reiterated Rating||Buy||N/A|
|6/3/2016||Morgan Stanley||Reiterated Rating||Overweight||N/A|
|5/23/2016||Bryan, Garnier & Co||Initiated Coverage||Buy||N/A|
|3/30/2016||Bank of America Corporation||Reiterated Rating||Buy||N/A|
|2/13/2016||Northland Securities||Reiterated Rating||Buy||N/A|
|2/8/2016||Susquehanna Bancshares Inc||Lower Price Target||Positive||$280.00 -> $220.00||N/A|
|1/18/2016||Credit Suisse Group||Upgrade||Buy||N/A|
|10/21/2015||William Blair||Reiterated Rating||Outperform||$276.00||N/A|
Earnings History for Shire PLC (NASDAQ:SHPG)Earnings History by Quarter for Shire PLC (NASDAQ SHPG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/2/2017||Q1 17||$3.22||$3.63||$3.57 billion||View||Listen|
|2/16/2017||Q416||$3.24||$3.37||$3.78 billion||$3.81 billion||View||N/A|
|11/1/2016||Q316||$3.21||$3.17||$3.57 billion||$3.45 billion||View||N/A|
|8/2/2016||Q216||$3.03||$3.38||$2.28 billion||$2.43 million||View||N/A|
|4/29/2016||Q1||$3.05||$3.19||$1.71 billion||$1.71 billion||View||Listen|
|2/11/2016||Q415||$2.89||$2.97||$1.69 million||$1.72 billion||View||Listen|
|10/23/2015||Q315||$2.87||$3.24||$1.63 billion||$1.58 billion||View||Listen|
|7/23/2015||Q215||$2.81||$2.63||$1.59 billion||$1.56 billion||View||Listen|
|4/30/2015||Q115||$2.56||$2.84||$1.47 billion||$1.49 billion||View||N/A|
|2/12/2015||Q115||$2.68||$2.63||$1.53 billion||$1.58 billion||View||N/A|
|10/24/2014||Q314||$2.47||$2.93||$1.46 billion||$1.55 billion||View||Listen|
|7/18/2014||Q214||$2.45||$2.67||$1.45 billion||$1.50 billion||View||N/A|
|5/1/2014||Q114||$2.22||$2.36||$1.38 billion||$1.35 billion||View||N/A|
|2/13/2014||Q413||$2.02||$2.26||$1.28 billion||$1.33 billion||View||N/A|
|10/24/2013||Q213||$1.65||$1.77||$1.23 billion||$1.24 billion||View||N/A|
|7/25/2013||$1.60||$1.79||$1.21 billion||$1.28 billion||View||N/A|
|5/2/2013||Q113||$1.56||$1.63||$1.21 billion||$1.16 billion||View||N/A|
|2/14/2013||Q412||$1.58||$1.58||$1.20 billion||$1.20 billion||View||N/A|
Earnings Estimates for Shire PLC (NASDAQ:SHPG)
2017 EPS Consensus Estimate: $14.74
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Shire PLC (NASDAQ:SHPG)
|Payout Ratio:||41.07% (Trailing 12 Months of Earnings) |
6.17% (Based on This Year's Estimates)
5.70% (Based on Next Year's Estimates)
Dividend History by Quarter for Shire PLC (NASDAQ SHPG)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Shire PLC (NASDAQ:SHPG)
Latest Headlines for Shire PLC (NASDAQ:SHPG)
Shire PLC (SHPG) Chart for Wednesday, October, 18, 2017